论文部分内容阅读
目的评价孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的临床疗效和安全性。方法将入选的87例小儿过敏性紫癜患者随机分成3组,治疗组(28例)每晚口服孟鲁司特钠及氯雷他定,对照1组(30例)每晚口服孟鲁司特钠,对照2组(29例)每晚口服氯雷他定,治疗结束时评价临床疗效及安全性。同时用ELISA法检测治疗前后患儿血清中白三烯B4(LTB4)和组胺含量。结果治疗结束时,治疗组有效率优于单用孟鲁司特钠组及氯雷他定组的有效率,治疗组的血清组胺和LTB4含量均明显低于其他两组的血清组胺和LTB4含量,以上差异均有统计学意义(P均<0.05)。3组均未出现明显的不良反应。结论孟鲁司特钠联合氯雷他定治疗过敏性紫癜的疗效优于分别单用孟鲁司特钠及和氯雷他定,可能与明显降低其血清组胺和LTB4含量有关,且疗效安全,值得临床推广。
Objective To evaluate the clinical efficacy and safety of montelukast sodium combined with loratadine in the treatment of children with Henoch-Schonlein purpura. Methods 87 cases of children with Henoch-Schonlein purpura were randomly divided into three groups. The treatment group (n = 28) received montelukast sodium and loratadine every night, while the control group 1 (n = 30) received montelukast Sodium and control group 2 (n = 29) were given loratadine orally every night, and the clinical efficacy and safety were evaluated at the end of treatment. At the same time, the levels of leukotriene B4 (LTB4) and histamine in the serum of children with and before treatment were detected by ELISA. Results At the end of treatment, the effective rate of the treatment group was superior to that of montelukast sodium group and loratadine group, and the serum histamine and LTB4 levels of the treatment group were significantly lower than those of the other two groups LTB4 content, the above differences were statistically significant (P all <0.05). No obvious adverse reactions were found in the three groups. Conclusion The efficacy of montelukast sodium combined with loratadine in the treatment of Henoch-Schonlein purpura is better than that of montelukast sodium and loratadine respectively, which may be related to the decrease of serum histamine and LTB4, and the efficacy is safe , It is worth clinical promotion.